Perspective Therapeutics share price logo

Perspective Therapeutics

AMEX: CATX

Small Cap

$2.86

+0.16

(+5.93%)

Live

as on

Perspective Therapeutics Stock Performance

as on September 18, 2026 at 6:13 am IST

  • Day's Low

    Day's High

    $2.74
    $2.92
    downward going graph

    4.20%

    Downside

    2.10%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.96
    $6.16
    downward going graph

    31.64%

    Downside

    115.38%

    Upside

    downward going graph

Perspective Therapeutics share price movements today

Previous Close
$2.70
Open
$2.76
Volume
902.4K
Market Cap
$311.6M
Day's Low - High
$2.74 - $2.92
52 Week Low - High
$1.96 - $6.16

Perspective Therapeutics Historical Returns

1 Month Return
-16.15 %
3 Month Return
-9.4 %
1 Year Return
-11.18 %
3 Year Return
+ 31.71 %
5 Year Return
0 %

Perspective Therapeutics Stock Fundamentals & Key Indicators

Check Perspective Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$311.6M

EPS (TTM)

-1.56

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.75

Industry PE ratio

-6.92

PEG Ratio

0.09862950638283816

EBITDA

-116.2M

Revenue (TTM)

366.0K

Profit Margin

-419.40%

Return On Equity TTM

-41.56%

Perspective Therapeutics Stock Valuation

Track how Perspective Therapeutics P/E has moved over time to understand its valuation trends.

Perspective Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-23.72x)

June 30, 2021

Industry (-6.92x)

December 31, 2025

Today (-1.96x)

December 31, 2025

Highest (-1.96x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.96x

Perspective Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Perspective Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Perspective Therapeutics image
Perspective Therapeutics
BUY$311.6MNA-1.75-419.40%0.00%
Edwards Lifesciences image
Edwards Lifesciences
BUY$49.4B-25.24%49.2877.98%0.00%
Medtronic image
Medtronic
BUY$120.0B-28.6%22.2466.69%3.04%
Abbott Laboratories image
Abbott Laboratories
BUY$178.4B-19.27%32.8156.80%2.43%
Stryker image
Stryker
BUY$105.7B1.72%28.3265.17%1.26%
See all

Stock Returns calculator for Perspective Therapeutics Stock including INR - Dollar returns

The Perspective Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Perspective Therapeutics investment value today

Current value as on today

₹1,02,693

Returns

₹2,693

(+2.69%)

Returns from Perspective Therapeutics Stock

-₹5,921 (-5.92%)

Dollar Impact

₹8,614 (+8.61%)

Analyst Recommendation on Perspective Therapeutics Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Perspective Therapeutics. Average target price of $12.29

Perspective Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Perspective Therapeutics.

What analysts predicted

76.73%UPSIDE

Target Price

$12.29

Current Price

$2.86

Analyzed by

10 Analysts

Target

$12.29

Perspective Therapeutics target price $12.29, a slight upside of 76.73% compared to current price of $2.86. According to 10 analysts rating.

Indian Investors' Interest in Perspective Therapeutics Stock

Search interest for Perspective Therapeutics Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-13% versus previous 30 day period

Perspective Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
-
-
0
0
0
-
0
0
Gross Profit
0
0
-
-
0
0
0
-
-1
0
Operating Income
-9
-13
-18
-44
-18
-24
-27
-39
-28
-29
EBITDA
-9
-12
-14
-41
-17
-21
-25
-37
-27
-26
Interest Expense
0
0
0
-
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
1
1
-
Income Before Tax
-9
-11
-15
-42
-15
-21
-25
-38
-26
-26
Income Tax Expense
-
-
-
-2
-
-
-
0
-
0
Net Income
-10
-12
-15
-40
-15
-21
-25
-37
-26
-26
Net Profit Margin
0.00%
0.00%
0.00%
-202.99%
-81.30%
-152.76%
-270.81%
0.00%
-1381.58%
100.00%

Perspective Therapeutics Annual Profit & Loss

All numbers in Millions USD

Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
7
9
10
10
5
1
1
-
Gross Profit
3
5
5
4
2
1
0
-
Operating Income
-5
-3
-3
-7
-9
-40
-66
-113
EBITDA
-5
-3
-3
-7
-8
-39
-64
-100
Interest Expense
-
-
-
-
-
0
0
0
Depreciation
0
0
0
0
0
0
2
3
Income Before Tax
-5
-3
-3
-7
-8
-40
-80
-104
Income Tax Expense
0
0
0
-
-
-2
-2
0
Net Income
-4
-3
-3
-7
-10
-46
-79
-103
Net Profit Margin
41.66%
52.93%
50.94%
42.76%
23.00%
100.00%
-58.60%
0.00%

Perspective Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-12
-11
-15
-40
-18
-21
-25
-37
-26
-26
Operating Cash Flow
13
-8
3
-26
-21
-19
-16
-24
-31
-20
Investing Cash Flow
-47
-3
-29
-138
-5
4
13
28
-109
15
Financing Cash Flow
166
122
0
0
9
0
0
0
164
0
Change in Cash
132
109
-25
-164
-17
-15
-2
3
23
-5

Perspective Therapeutics Annual Cash Flow

All numbers in Millions USD

Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-5
-3
-3
-7
-10
-46
-79
-103
Operating Cash Flow
-5
-3
-2
-7
-10
-36
-18
-82
Investing Cash Flow
0
0
0
0
-28
24
-218
41
Financing Cash Flow
7
0
64
0
0
0
289
10
Change in Cash
2
-2
61
-7
-7
-11
52
-30

Mutual Funds that own Perspective Therapeutics Stock

Check out the Mutual Funds with significant holdings in Perspective Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.742993%
4272689
Fidelity Salem Street Trust
0.618746%
706309
Fidelity Concord Street Trust
0.585807%
668709
VANGUARD SCOTTSDALE FUNDS
0.299788%
342213
VANGUARD WORLD FUND
0.254772%
290827
See all

Global Institutional Holdings in Perspective Therapeutics

Funds
Holdings
Vanguard
4.62%
SPDR
4.11%
iShares
4.09%
Dimensional
0.59%
Schwab
0.41%
See all

Perspective Therapeutics News & Key Events

  • img

    Today's Timeline - 14 September

    Mon, 04:18 PM

    -

    Perspective Therapeutics announces collaboration with Merck to evaluate PSV359 with Keytruda in solid tumors under a Phase 1/2a trial.

Insights on Perspective Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CATX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 43.0K → 81.0K (in $), with an average increase of 24.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 18.7% return, outperforming this stock by 29.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -26.18M → -26.78M (in $), with an average decrease of 2.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, CATX stock has moved down by -16.1%

About Perspective Therapeutics

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
OrganisationPerspective Therapeutics
Headquarters2401 Elliott Avenue, Seattle, WA, United States, 98121
IndustryMedical Devices
CEOMr. Johan M. Spoor
E-voting on sharesClick here to vote

Key Management of Perspective Therapeutics

Name

Title

Mr. Johan M. Spoor

CEO & Director

Mr. Joel David Sendek

CFO & Principal Financial Officer

Dr. Markus Puhlmann M.B.A., M.D.

Chief Medical Officer

Mr. Jonathan R. Hunt

Chief Accounting Officer

Mr. Andrew Bright

Executive Vice President of Brachytherapy

Dr. Michael K. Schultz Ph.D.

Co-Founder & Senior Scientific Advisor

Mr. Shane Cobb

Executive Vice President of Operations

Dr. Paul Lyne Ph.D.

Chief Science Officer

Ms. Annie J. Cheng

Vice President of Investor Relations

Mr. Chris Nenno

General Counsel & Corporate Secretary

FAQs

What is Perspective Therapeutics share price today?

Perspective Therapeutics share price today is $2.86 as on . Perspective Therapeutics share today touched a day high of $2.92 and a low of $2.74.

What is the 52 week high and 52 week low for Perspective Therapeutics share?

Perspective Therapeutics share touched a 52 week high of $6.16 on and a 52 week low of $1.96 on . Perspective Therapeutics stock price today i.e. is trending at $2.86,which is 53.57% down from its 52 week high and 46.29% up from its 52 week low.

What is Perspective Therapeutics's market capitalisation today?

Perspective Therapeutics market capitalisation is $0.00T as on .

How to invest in Perspective Therapeutics Stock (CATX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Perspective Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Perspective Therapeutics Shares that will get you 0.5245 shares as per Perspective Therapeutics share price of $2.86 per share as on September 18, 2026 at 12:43 am IST.

What is the minimum amount required to buy Perspective Therapeutics Stock (CATX) from India?

Indian investors can start investing in Perspective Therapeutics (CATX) shares with as little as ₹95.93 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.30 in Perspective Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Perspective Therapeutics share’s latest price of $2.86 as on September 18, 2026 at 12:43 am IST, you will get 3.4965 shares of Perspective Therapeutics. Learn more about fractional shares .